Intervacc presents to the capital market on three occasions in March

Intervacc reports that more than 30,000 horses have been vaccinated with its Strangvac vaccine and that several field studies and multiple scientific articles have been completed/published. The company will present updates to investors at the DNB/Carnegie Healthcare Seminar, Stora Aktiedagarna and Stockholm Corporate Finance Life Science capital markets days in March and intends to summarize its current situation for shareholders. This is a positive commercial and scientific validation signal but is informational rather than transformative for valuation.

Analysis

The company's recent commercial signals materially shift its negotiating leverage with contract manufacturers and distributors: what was previously a development-stage valuation should be re-priced toward a commercialization multiple if supply contracts and repeat order cadence are visible in the next 3–12 months. That transition favors scalable CMOs and logistics partners rather than pure research-stage biotech peers, creating a two-tier domestic market where manufacturing capacity becomes the binding constraint and a key value driver.

Second-order winners include global protein expression and fill/finish suppliers (pricing power, better utilization) and veterinary distribution networks that can cross-sell ancillary products; losers are small single-product equine incumbents and niche academic spinouts that lack scale. Expect bidding for capacity to raise short-term CMO utilization 5–15% and for procurement timelines to lengthen 2–6 months as firms prioritize higher-margin recombinant programs, which could push up lead times and capex plans across the sector within a year.

Principal risks hinge on execution: a manufacturing failure, a high-profile adverse event, or slower-than-expected channel adoption can reverse sentiment quickly—any of those would likely manifest within weeks-to-months and compress multiples back toward development-stage levels. Conversely, clear, repeatable order flow and signed multi-year supply agreements would validate a re-rate and could produce 30–50% valuation expansion over 12 months.

The market is split between underweighting platform optionality and overestimating immediate revenue scale from a niche veterinary market. The prudent stance is to trade the path to scale (CMO deals, repeat orders, distributor agreements) rather than the narrative presentations themselves: price in real contracts and cadence, not poster-board milestones.

Key Decisions for Investors

• Event-driven long (company equity, local listing) into March investor days — enter 1–2 weeks ahead, trim into strength. Target +10–20% in 1–3 months if management announces binding supply/distribution deals; hard stop -12% on headline manufacturing/regulatory miss.
• Long Catalent (CTLT) equity — 6–12 month horizon to capture incremental recombinant protein manufacturing demand. Risk: company-specific execution and broader market selloff; reward: 20–35% upside if utilization/contract wins accelerate; position size 3–6% of biotech allocation.
• Paired trade: long CTLT (CTLT) / short XBI (SPDR S&P Biotech ETF) — horizon 3–12 months. Rationale: favor scalable service providers over valuation-sensitive small-cap developers; target spread capture 15–25% relative performance, cap downside via 10% trailing stop on both legs.
• Buy Thermo Fisher (TMO) 9–12 month call spread (debit) to express defensive exposure to increased protein-handling and analytics demand while limiting capital. Structure to cap cost and target asymmetric upside (aim for 2.5–3x payoff vs premium) if sector capex and consumables demand accelerate.